ResMed shareholders also sleep well at night

August 6, 2018

Sleep device maker ResMed this morning reported a 13% increase in revenue for the year ended 30 June 2018 together with a 27% increase in operating income. Chief Executive, Mick Farrell, was reported as saying that “we closed out the year with strong performance across all aspects of our business, from solid top-line revenue growth, driven by geographically balanced results across our entire portfolio of offerings”.  The company is well positioned for fiscal year 2019.

Resmed is one of Morgan Wealth’s core shareholdings and has produced a return of 47% for the 12 months ended 31 July 2018.

Our Top Stock Picks
Total returns on capital growth and dividends for 10 months ended 31 October 2019. Past performance is not a reliable indicator of future performance.
Zip Co Ltd
244.95%
Nanosonics
139.44%
Afterpay Touch
132.74%
Nearmap Ltd
78.67%
Appen Limited
71.08%
CSL Limited
39.71%
Goodman Group
36.78%
ResMed Inc
34.26%
Atlas Arteria
33.07%
Macquarie Group
26.57%
ASX200 Accum Index (comparison)
22.12%